Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Tmunity Therapeutics
3400 Civic Center Building 8-116
Philadelphia, PA 19104

Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells to treat a wide range of disease indications. Tmunity is developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms that exhibit best-in-class control over T cell activation and direction in vivo, as well as proprietary technologies to activate, expand, and genetically engineer T cells from peripheral blood, cord blood and tumors. The company is rapidly advancing toward the clinic personalized next-generation immunotherapies for oncology, infectious diseases and autoimmune disease. The founding team includes experts in T-cell biology, manufacturing, regulatory affairs, and clinical development, who collectively have an unparalleled track record of executing safe and effective cell and gene therapy clinical trials. In addition, Tmunity's manufacturing platform has a proven track record of success in supporting multi-center clinical studies across diverse therapeutic indications.

Key Contact
Name
Anne Chew
Title
CEO
E-Mail
Funding Events

Date
Amount
Type
Investors
Valuation
01/13/16 $10,000,000 Lilly Asia Ventures
Penn Medicine
undisclosed
10/31/19 $75,000,000 Series B Be The Match BioTherapies
BrightEdge Ventures
Gilead Sciences
University of Pennsylvania
Westlake Village BioPartners
undisclosed


Featured Reading